Antioxidant capacity in Fasciola hepatica patients before and after treatment with triclabendazole alone or in combination with ascorbic acid (vitamin C) and tocofersolan (vitamin E).
The aim of the present study was to investigate the effect of triclabendazole (CAS 68786-66-3) therapy alone or in combination with ascorbic acid (vitamin C, CAS 50-81-7) and tocofersolan (vitamin E, CAS 30999-06-5), in Fasciola hepatica patients, on Lipo-peroxidation (LPO) and blood antioxidant capacity. 32 Fasciola hepatica patients were divided into two groups (16 acute and 16 chronic). Each group was divided into two subgroups of 8 patients each. One subgroup was given two consecutive oral doses each of 10 mg/kg body weight of triclabendazole suspension and the other received vitamin C (1000 mg/day) and vitamin E (600 mg/day) for two months, together with the same dose of triclabendazole given to the first subgroup. Ten healthy subjects served as controls. The results revealed a significant increase in serum and erythrocyte lipid peroxide levels and a significant decrease in glutathione levels as well as in glutathione peroxidase (GPX) and superoxide dismutase (SOD) activities in all study groups compared to their corresponding control values. After triclabendazole treatment, pronounced improvements in all studied parameters were observed which could be attributed to the fasciolicidal effect of the drug. The significant improvement of SOD and GPX activities and in lipid peroxide levels after vitamins supplementation as compared to their corresponding values after treatment with triclabendazole alone could be explained on the basis of the potent action of these vitamins in protection against oxidative damage.
Rehim
Wafaa M
WM
Department of Biochemistry, Medical Research Institute, Alexandria University, Alexandria, Egypt. wafaa1962@hotmail.com
Sharaf
Iman A
IA
Hishmat
Mohamed
M
el-Toukhy
Mervat A
MA
Rawash
Nayer Abo
NA
Fouad
Howayda N
HN
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000871:Anthelmintics / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism* / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002908:Chronic Disease; D004338:Drug Combinations; D004912:Erythrocytes / Q000201:enzymology / Q000378:metabolism; D005211:Fascioliasis / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D005978:Glutathione / Q000097:blood; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D008054:Lipid Peroxides / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D013482:Superoxide Dismutase / Q000097:blood; D000077682:Triclabendazole; D014810:Vitamin E / Q000627:therapeutic use*
D000871:Anthelmintics; D000975:Antioxidants; D001562:Benzimidazoles; D004338:Drug Combinations; D008054:Lipid Peroxides; D014810:Vitamin E; D000077682:Triclabendazole; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005978:Glutathione; D001205:Ascorbic Acid